Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-12
2006-12-12
Wang, Shengjun (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S118000, C546S273400, C548S302100, C548S304400, C548S309700, C548S306100, C514S338000, C514S394000, C514S393000
Reexamination Certificate
active
07148234
ABSTRACT:
Methods of treating IL-6 involved diseases with EP4 receptor ligands, including EP4 receptor antagonists. Assays to determine the effect of test compounds on PGE2-induced whole blood cells activation.
REFERENCES:
patent: 4536507 (1985-08-01), Rokach et al.
patent: 5972965 (1999-10-01), Taniguchi et al.
patent: 6710054 (2004-03-01), Nakao et al.
patent: WO 00/16760 (2000-03-01), None
patent: WO 00/16760 (2000-03-01), None
patent: WO 00/18744 (2000-04-01), None
patent: WO 02/32900 (2002-04-01), None
patent: WO 02/32900 (2002-04-01), None
patent: WO 02/50033 (2002-06-01), None
R. W. Alexander, et al., “Inflammation and Coronary Artery Disease”, The New England Journal of Medicine, Aug. 18, 1994, pp. 468-469, vol. 331, No. 7.
C. S. R. Baker, et al., “Cyclooxygenase-2 is Widely Expressed in Atherosclerotic Lesions Affecting Native and Transplanted Human Coronary Arteries and Colocalized with Inducible Nitric Oxide Synthase and Nitrotyrosine Particularly in Macrophages”, Arterioscler Thromb Vascular Biology, 1999, pp. 646-655, vol. 19.
T. A. Blaine, et al., “Modulation of the Production of Cytokines in Titanium-Stimulated Human Peripheral Blood Monocytes by Pharmacological Agents”, The Journal of Bone and Joint Surgery, Oct. 1997, pp. 1519-1528, vol. 79-A, No. 10.
P. K. Bourassa, et al., “Estrogen Reduces Atherosclerotic Lesion Development in Apolipoprotein E-deficient Mice”, Proc. Natl. Academy of Science, Sep. 1996, pp. 10022-10027, vol. 93.
F. R. Cochran, et al., “Interleukin-6 Can Prime THP-1 Macrophages for Enhanced Production of Tumor Necrosis Factor-alpha in Response to LPS”, Immunopharmacology, 1992, pp. 97-103, vol. 23.
R. A. Coleman, et al., “International Union of Pharmacology Classification of Prostanoid Receptors: Properties, Distrubtion, and Structure of the Receptors and Their Subtypes”, Pharmacological Reviews, 1994, pp. 205-209, vol. 46, No. 2.
U. Ikeda, et al., “Interleukin 6 Stimulates Growth of Vascular Smooth Muscle Cells in a PDGF-dependent Manner,” American Journal of Physiology, May 1991, pp. H1713-H1717, vol. 260 No. 5.
K. Kauser, et al., “Effect of 17Beta-Estradiol on Atherosclerotic Lesion Formation In ApoE-Deficient Mice”, Journal of Vascular Research, 1996, p. 48, vol. 33, Suppl 1.
H. Kishikawa, et al., “Localization of T Lymphocytes and Macrohpghages Expressing IL-1, IL-2 Receptor, IL-6 and TNF in Human Aortic Intima. Role of Cell-mediated Immunity in Human Atherogenesis”, Virchows Archive A Pathological Anatomy and Histopathology, 1993,.
P. Libby, et al., “The Role of Macrophages in Atherogenesis”, Current Opinion in Lipidology, 1993, pp. 355-363, vol. 4.
G. Liuzzo, et al., “The Prognostic Value of C-Reactive Protein and Serum Amyloid a Protein in Severe Unstable Angina”, The New England Journal of Medicine, Aug. 18, 1994, pp. 417-424, vol. 331, No. 7.
S. Monkada, et al., “An enzyme Isolated from Arteries Transforms Prostaglandin Endoperoxides to an Unstable Substance that Inhibits Platelet Aggregation”, Nature, Oct. 21, 1976, pp. 663-665, vol. 263.
P. Needleman, et al., “The Discovery and Function of COX-2”, The Journal of Rheumatology, 1997, pp. 6-8, vol. 24, Suppl. 49.
M. Negishi, et al., “Molecular Mechanisms of Diverse Actions of Prostanoid Receptors”, Biochimica et Biophysica Acta, 1995, pp. 109-120, vol. 1259.
P. M. Ridker, et al., “Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men”, The New England Journal of Medicine, Apr. 3, 1997, pp. 973-979, vol. 336, No. 14.
R. Ross, et al., “The Pathogenesis of Atherosclerosis: A Perspective for the 1990s”, Nature, Apr. 29, 1993, pp. 801-809, vol. 362.
Y. Seino, et al., Interleukin 6 Gene Transcripts are Expressed in Human Atherosclerotic Lesions, Cytokine, Jan. 1994, pp. 87-91, vol. 6, No. 1.
V. Stemme, et al., “Expression of Cyclo-Oxygenase-2 in Human Atherosclerotic Carotid Arteries”, European Journal of Vascular and Endovascular Surgery, 2000, pp. 146-152, vol. 20.
D. A. Sukovich, et al., “Expression of Interleukin-6 Atherosclerotic Lesions of Male ApoE-Knockout Mice Inhibition by 17Beta-Estradiol”, Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, pp. 1498-1505, vol. 18, No. 9.
A. C. Van Der Wal, et al., “Site of Intimal Rupture or Erosion of Thrombosed Coronary Atherosclerotic Plaques Is Characterized by an Inflammatory Process Irrespective of the Dominant Plaque Morphology”, Circulation, Jan. 1994, pp. 36-44, vol. 89, No. 1.
K. Yoshizaki, et al., “Therapy of Rheumatoid Arthritis by Blocking IL-6 Signal Transduction with a Humanized Anti-IL-6 Receptor Antibody”, Springer Seminars in Immunopathology, 1998, pp. 247-259, vol. 20.
Shimojo Masato
Taniguchi Kana
Ashbrook Charles W.
Chong Yong S.
Kurlandsky David R.
Pfizer Inc.
Wang Shengjun
LandOfFree
Use of EP4 receptor ligands in the treatment of IL-6... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of EP4 receptor ligands in the treatment of IL-6..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of EP4 receptor ligands in the treatment of IL-6... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3714248